undamentalytics Newsletter
Sign in

NRX Pharmaceuticals, Inc. revenue

NRX Pharmaceuticals, Inc.'s revenue was $1.2m in fiscal 2025. Over the last twelve months it was $3.4m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue001,2253,394
Gross profit—07201,583

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Therapy $854,000 —
Procedures $371,000 —

These categories overlap or exclude eliminations, so shares aren't shown.

From NRX Pharmaceuticals, Inc.'s 10-K filed March 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
NRX Pharmaceuticals, Inc. $3.4m — —
Xenetic Biosciences, Inc. $3.3m 33.3% 14.7%
Upstream Bio, Inc. $3.2m 16.0% —
Aligos Therapeutics, Inc. $3.7m 19.4% -5.5%
Dyadic International Inc $3.8m -8.0% 3.4%
DBV Technologies S.a. $3.8m -31.6% -11.6%

Compare with peers

Head to head: NRXP vs XBIONRXP vs UPBALGS vs NRXP

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from NRX Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to NRX Pharmaceuticals, Inc.